MedTrace Logo

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

NCT07370506 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-29

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.

Conditions

Interventions

DRUG

Telmisartan

Telmisartan administered orally once daily as cardioprotective therapy during doxorubicin-based chemotherapy.

DRUG

Doxorubicin (DOX)

Standard doxorubicin-based chemotherapy according to institutional protocol.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-01-31
Completion
2027-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07370506 on ClinicalTrials.gov